Connection

WILLEM OVERWIJK to Lymphocyte Activation

This is a "connection" page, showing publications WILLEM OVERWIJK has written about Lymphocyte Activation.
Connection Strength

0.601
  1. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr Opin Immunol. 2017 Aug; 47:103-109.
    View in: PubMed
    Score: 0.102
  2. Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother. 2015 Jul; 64(7):911-21.
    View in: PubMed
    Score: 0.088
  3. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009 Nov 20; 31(5):787-98.
    View in: PubMed
    Score: 0.060
  4. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 2009 May 26; 27(25-26):3484-8.
    View in: PubMed
    Score: 0.057
  5. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S76-80.
    View in: PubMed
    Score: 0.030
  6. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 01 31; 11(1):661.
    View in: PubMed
    Score: 0.030
  7. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol. 2000 Jan 15; 164(2):562-5.
    View in: PubMed
    Score: 0.030
  8. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620.
    View in: PubMed
    Score: 0.028
  9. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol. 1998 Nov 15; 161(10):5313-20.
    View in: PubMed
    Score: 0.028
  10. Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clin Cancer Res. 2017 Oct 15; 23(20):6151-6164.
    View in: PubMed
    Score: 0.025
  11. Temporally Programmed CD8a+ DC Activation Enhances Combination Cancer Immunotherapy. Cell Rep. 2016 12 06; 17(10):2503-2511.
    View in: PubMed
    Score: 0.024
  12. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunol Res. 2016 11; 4(11):983-994.
    View in: PubMed
    Score: 0.024
  13. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol. 2016 07 03; 35(4):325-339.
    View in: PubMed
    Score: 0.021
  14. Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88.
    View in: PubMed
    Score: 0.016
  15. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother. 2008 Jan; 31(1):1-6.
    View in: PubMed
    Score: 0.013
  16. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007 Oct; 19(10):1213-21.
    View in: PubMed
    Score: 0.013
  17. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005 Mar 01; 174(5):2591-601.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.